VEGFA and kidney cancer: Targeted therapy for kidney cancer includes three groups of drugs: tyrosine kinase inhibitors (TKIs), mTOR serine-threonine kinase inhibitors, and anti–vascular endothelial growth factor (VEGF) monoclonal antibody (Hsieh et al., 2017).